Literature DB >> 24506068

The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells.

Martin L Read1, Robert I Seed, Jim C W Fong, Bhavika Modasia, Gavin A Ryan, Rachel J Watkins, Teresa Gagliano, Vicki E Smith, Anna L Stratford, Perkin K Kwan, Neil Sharma, Olivia M Dixon, John C Watkinson, Kristien Boelaert, Jayne A Franklyn, Andrew S Turnell, Christopher J McCabe.   

Abstract

The PTTG1-binding factor (PBF/PTTG1IP) has an emerging repertoire of roles, especially in thyroid biology, and functions as a protooncogene. High PBF expression is independently associated with poor prognosis and lower disease-specific survival in human thyroid cancer. However, the precise role of PBF in thyroid tumorigenesis is unclear. Here, we present extensive evidence demonstrating that PBF is a novel regulator of p53, a tumor suppressor protein with a key role in maintaining genetic stability, which is infrequently mutated in differentiated thyroid cancer. By coimmunoprecipitation and proximity-ligation assays, we show that PBF binds specifically to p53 in thyroid cells and significantly represses transactivation of responsive promoters. Further, we identify that PBF decreases p53 stability by enhancing ubiquitination, which appears dependent on the E3 ligase activity of Mdm2. Impaired p53 function was evident in a transgenic mouse model with thyroid-specific PBF overexpression (transgenic PBF mice), which had significantly increased genetic instability as indicated by fluorescent inter simple sequence repeat-PCR analysis. Consistent with this, approximately 40% of all DNA repair genes examined were repressed in transgenic PBF primary cultures, including genes with critical roles in maintaining genomic integrity such as Mgmt, Rad51, and Xrcc3. Our data also revealed that PBF induction resulted in up-regulation of the E2 enzyme Rad6 in murine thyrocytes and was associated with Rad6 expression in human thyroid tumors. Overall, this work provides novel insights into the role of the protooncogene PBF as a negative regulator of p53 function in thyroid tumorigenesis, in which PBF is generally overexpressed and p53 mutations are rare compared with other tumor types.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24506068      PMCID: PMC4759943          DOI: 10.1210/en.2013-1646

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  60 in total

1.  Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.

Authors:  M S Rodriguez; J M Desterro; S Lain; D P Lane; R T Hay
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

2.  Roles for APIS and the 20S proteasome in adenovirus E1A-dependent transcription.

Authors:  Mozhgan Rasti; Roger J A Grand; Ahmed F Yousef; Michael Shuen; Joe S Mymryk; Phillip H Gallimore; Andrew S Turnell
Journal:  EMBO J       Date:  2006-06-08       Impact factor: 11.598

3.  The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification.

Authors:  Iain J Nixon; Ian Ganly; Snehal G Patel; Frank L Palmer; Monica M Di Lorenzo; Ravinder K Grewal; Steven M Larson; R Michael Tuttle; Ashok Shaha; Jatin P Shah
Journal:  Thyroid       Date:  2013-06       Impact factor: 6.568

4.  Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis.

Authors:  R Yu; A P Heaney; W Lu; J Chen; S Melmed
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

5.  Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.

Authors:  Davide Danovi; Erik Meulmeester; Diego Pasini; Domenico Migliorini; Maria Capra; Ruth Frenk; Petra de Graaf; Sarah Francoz; Patrizia Gasparini; Alberto Gobbi; Kristian Helin; Pier Giuseppe Pelicci; Aart G Jochemsen; Jean-Christophe Marine
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

6.  A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer.

Authors:  Vicki E Smith; Martin L Read; Andrew S Turnell; Rachel J Watkins; John C Watkinson; Greg D Lewy; Jim C W Fong; Sally R James; Margaret C Eggo; Kristien Boelaert; Jayne A Franklyn; Christopher J McCabe
Journal:  J Cell Sci       Date:  2009-08-25       Impact factor: 5.285

7.  The expression of the MDM2 gene, a p53 binding protein, in thyroid carcinogenesis.

Authors:  M Zou; Y Shi; S al-Sedairy; S S Hussain; N R Farid
Journal:  Cancer       Date:  1995-07-15       Impact factor: 6.860

8.  p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents.

Authors:  T Grombacher; U Eichhorn; B Kaina
Journal:  Oncogene       Date:  1998-08-20       Impact factor: 9.867

Review 9.  Genomic and epigenetic instability in colorectal cancer pathogenesis.

Authors:  William M Grady; John M Carethers
Journal:  Gastroenterology       Date:  2008-09-04       Impact factor: 22.682

10.  Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

Authors:  Mingzhao Xing; Ali S Alzahrani; Kathryn A Carson; David Viola; Rossella Elisei; Bela Bendlova; Linwah Yip; Caterina Mian; Federica Vianello; R Michael Tuttle; Eyal Robenshtok; James A Fagin; Efisio Puxeddu; Laura Fugazzola; Agnieszka Czarniecka; Barbara Jarzab; Christine J O'Neill; Mark S Sywak; Alfred K Lam; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Hirotaka Nakayama; Ralph P Tufano; Sara I Pai; Martha A Zeiger; William H Westra; Douglas P Clark; Roderick Clifton-Bligh; David Sidransky; Paul W Ladenson; Vlasta Sykorova
Journal:  JAMA       Date:  2013-04-10       Impact factor: 56.272

View more
  15 in total

1.  Prognostic implications of securin expression and sub-cellular localization in human breast cancer.

Authors:  N Gurvits; H Repo; E Löyttyniemi; M Nykänen; J Anttinen; T Kuopio; K Talvinen; P Kronqvist
Journal:  Cell Oncol (Dordr)       Date:  2016-03-16       Impact factor: 6.730

2.  Interactome Analysis Reveals a Novel Role for RAD6 in the Regulation of Proteasome Activity and Localization in Response to DNA Damage.

Authors:  Hongli An; Lu Yang; Chen Wang; Zhixue Gan; Haihui Gu; Tao Zhang; Xin Huang; Yan Liu; Yufeng Li; Shing-Jyh Chang; Jianghua Lai; Ya-Bin Li; Su Chen; Fang-Lin Sun
Journal:  Mol Cell Biol       Date:  2017-03-01       Impact factor: 4.272

3.  PTTG and PBF Functionally Interact with p53 and Predict Overall Survival in Head and Neck Cancer.

Authors:  Martin L Read; Bhavika Modasia; Alice Fletcher; Rebecca J Thompson; Katie Brookes; Peter C Rae; Hannah R Nieto; Vikki L Poole; Sally Roberts; Moray J Campbell; Kristien Boelaert; Andrew S Turnell; Vicki E Smith; Hisham Mehanna; Christopher J McCabe
Journal:  Cancer Res       Date:  2018-08-28       Impact factor: 12.701

4.  Pro-invasive Effect of Proto-oncogene PBF Is Modulated by an Interaction with Cortactin.

Authors:  Rachel J Watkins; Waraporn Imruetaicharoenchoke; Martin L Read; Neil Sharma; Vikki L Poole; Erica Gentilin; Sukhchain Bansal; Emy Bosseboeuf; Rachel Fletcher; Hannah R Nieto; Ujjal Mallick; Allan Hackshaw; Hisham Mehanna; Kristien Boelaert; Vicki E Smith; Christopher J McCabe
Journal:  J Clin Endocrinol Metab       Date:  2016-09-07       Impact factor: 5.958

5.  Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer.

Authors:  M L Read; J C Fong; B Modasia; A Fletcher; W Imruetaicharoenchoke; R J Thompson; H Nieto; J J Reynolds; A Bacon; U Mallick; A Hackshaw; J C Watkinson; K Boelaert; A S Turnell; V E Smith; C J McCabe
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

Review 6.  New Insights in Thyroid Cancer and p53 Family Proteins.

Authors:  Livia Manzella; Stefania Stella; Maria Stella Pennisi; Elena Tirrò; Michele Massimino; Chiara Romano; Adriana Puma; Martina Tavarelli; Paolo Vigneri
Journal:  Int J Mol Sci       Date:  2017-06-21       Impact factor: 5.923

7.  Higher circular RNA_0015278 correlates with absence of extrathyroidal invasion, lower pathological tumor stages, and prolonged disease-free survival in papillary thyroid carcinoma patients.

Authors:  Huajie Ding; Xiaojie Wang; Huiling Liu; Lei Na
Journal:  J Clin Lab Anal       Date:  2021-05-09       Impact factor: 2.352

8.  ICAM1 Is a Potential Cancer Stem Cell Marker of Esophageal Squamous Cell Carcinoma.

Authors:  Sheng-Ta Tsai; Po-Jen Wang; Nia-Jhen Liou; Pei-Shan Lin; Chung-Hsuan Chen; Wei-Chao Chang
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

9.  Functional consequences of the first reported mutations of the proto-oncogene PTTG1IP/PBF.

Authors:  W Imruetaicharoenchoke; A Fletcher; W Lu; R J Watkins; B Modasia; V L Poole; H R Nieto; R J Thompson; K Boelaert; M L Read; V E Smith; C J McCabe
Journal:  Endocr Relat Cancer       Date:  2017-07-04       Impact factor: 5.678

10.  PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival.

Authors:  Heli Repo; Natalia Gurvits; Eliisa Löyttyniemi; Marjukka Nykänen; Minnamaija Lintunen; Henna Karra; Samu Kurki; Teijo Kuopio; Kati Talvinen; Mirva Söderström; Pauliina Kronqvist
Journal:  BMC Cancer       Date:  2017-10-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.